Back to top
more

Grifols (GRFS)

(Real Time Quote from BATS)

$8.86 USD

8.86
165,984

+0.02 (0.23%)

Updated Nov 4, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%

Galectin Therapeutics, Inc. (GALT) shares rose nearly 17% in the last trading session.

    Amgen Files for Xgeva Label Expansion, To Include Myeloma

    Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.

      Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk

      A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control

        AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

        AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

          Tirthankar Chakraborty headshot

          New Strong Buy Stocks for March 30th

          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

            Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%

            Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares rose over 18% on the day.

              5 Cheap PEG Picks for Value Investors Right Now

              PEG is the ratio with the earnings growth component in it.

                Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod

                Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.

                  AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

                  London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.

                    Is Grifols a Great Stock for Value Investors?

                    Let's focus on Grifols, S.A. (GRFS) stock and find out if it is a good choice for value-oriented investors right now or not.

                      Aurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session

                      Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares rose above 8% on the day.

                        Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%

                        Esperion Therapeutics, Inc. (ESPR) moved big last session, as its shares rose above 8% on the day.

                          Tirthankar Chakraborty headshot

                          New Strong Buy Stocks for March 9th

                          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                            Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5%

                            Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise almost 7% in the last trading session.

                              Hologic (HOLX) to Divest Blood Screening Business to Grifols

                              Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.

                                Kevin Matras headshot

                                The Power of New Analyst Coverage

                                Kevin Matras shows why stocks with new analyst coverage are stocks you want to have. Highlighted stocks include GRFS, PRGN, GWRE, ABM and THG.